13 results about "Ceftazidime" patented technology

The application discloses a material for preventing tissue adhesion and hemostasis and a preparation method thereof, and relates to the technical field of medical biomaterials.The carboxymethyl cellulose, chitosan and vancomycin / ceftazidime are synergistically matched, so that the three functions of hemostasis, adhesion prevention and antibiosis are integrated;meanwhile, the water absorption and gelation of the carboxymethyl cellulose and the blood coagulation activation of the chitosan can jointly strengthen the hemostasis effect; the tissue barrier function of the chitosan and the gel isolation of the carboxymethyl cellulose can jointly improve the adhesion prevention performance; the broad-spectrum antibiosis of the vancomycin and the ceftazidime can respond to the infection risk in different surgical scenes; the material preparation process is simple, the dosage form can be adjusted according to different surgical scenes, the material has good biocompatibility and can be completely degraded, the problem that the existing medical materials have single function and are difficult to meet the needs of complex surgical wounds is solved, and the material has significant clinical application value.

The invention provides a synthetic method of a tazobactam intermediate debrominated sulfoxide ester. According to the method, 6-APA is taken as an initial raw material, the 6-APA is prepared through a bromination-(esterification-oxidation)-debromination three-step synthesis reaction one-pot method, acid-catalyst-sodium hypochlorite-benzophenone hydrazone combination is used in the esterification-oxidation step to realize the one-pot reaction, and meanwhile, a hazardous chemical substance peracetic acid is removed. In the debromination step, a combination of illumination, a catalyst and ascorbic acid is adopted to replace zinc powder. Compared with the traditional process, the method has the advantages that the production process is simplified, the safety is better, the molar yield is increased by 13% or above, and the method is suitable for industrial production.

The invention discloses application of gentamicin and ceftazidime in enhancing the drug sensitivity of serratia marcescens, and belongs to the field of biological medicine. The serratia marcescens is a strain carrying drug-resistant genes such as OqxB and mdtC, the mass ratio of gentamicin to ceftazidime is (1: 10)-(1: 50), the synergistic effect of gentamicin and ceftazidime is the strongest under the ratio, the sensitivities of serratia marcescens to gentamicin and ceftazidime can be recovered by 12.5 times and 42 times respectively, MBC is synchronously and greatly reduced, and the serratia marcescens has the dual effects of drug sensitivity enhancement and infection treatment; the single dosage is reduced, so that the cost is reduced, and the potential damage of the medicine to a host is reduced while the treatment effect is ensured. The prodigiosin is effective to serratia marcescens carrying various drug-resistant genes such as OqxB, mdtC, AAC (6 ')-Ic, KdpE and CpxA, cost is saved for prevention, control and treatment of serratia marcescens in animal husbandry, and important reference is provided for safe extraction and utilization of prodigiosin and clinical treatment of human serratia marcescens infection.

The invention discloses a tazobactam crude product mother liquor recovery method, which belongs to the technical field of chemical process, and comprises the following steps: S1, pretreatment: adjusting the pH value of the tazobactam crude product mother liquor to 2.5-4.0; s2, adsorption: adsorbing the pretreated crude product mother liquor through an ion exchange resin column at the temperature of 5-20 DEG C; s3, desorption: using absolute ethyl alcohol as a desorption agent, carrying out desorption on the ion exchange resin column after adsorption, and collecting a desorption solution; s4, crystallization: concentrating the desorption solution at the temperature of not more than 35 DEG C, adding a tazobactam seed crystal, cooling to 0-5 DEG C, and growing the crystal for 20-40 minutes; and S4, suction filtration and drying: performing suction filtration on the material after crystal growing to obtain wet powder, and drying the wet powder to constant weight under the conditions that the temperature is 30-35 DEG C and the pressure is lower than-0.080 MPa to obtain a tazobactam product.

The application belongs to the technical field of medicine synthesis, and particularly relates to a preparation method of ceftazidime hydrochloride and intermediates thereof. The application takes D-7-ACA as raw material, D-7-ACA is salted with a sodium bicarbonate aqueous solution, and then reacts with pyridine under the action of a catalyst to obtain a 7-PYCA reaction liquid; the reaction liquid is subjected to a condensation reaction with ceftazidime active ester to obtain ceftazidime tert-butyl ester; the obtained ceftazidime tert-butyl ester is subjected to a deprotection reaction under the condition of formic acid and hydrochloric acid, and finally crystallization is performed to obtain ceftazidime hydrochloride. The method has the advantages of low cost, high yield and purity, simple process, less waste, high production capacity, and good industrialization value.

This invention discloses a method for determining ceftazidime and its formulation polymers, comprising the following steps: 1) preparing a system suitability solution; 2) preparing a reference solution; 3) preparing a test solution for ceftazidime for injection; 4) determination: injecting the system suitability solution, reference solution, and test solution into a liquid chromatograph, respectively, and performing determination using reversed-phase chromatography, wherein the mobile phase of the reversed-phase chromatography contains mobile phase A and mobile phase B, mobile phase A being an aqueous formic acid solution and mobile phase B being methanol. The chromatogram obtained by the method of this invention has a stable baseline, can detect multiple polymeric impurities of ceftazidime, and exhibits good separation of each impurity; the method of this invention has good specificity and system suitability, and its linearity, sensitivity, repeatability, intermediate precision, and robustness are all good; furthermore, the test solution and reference solution of this invention have high stability.

The invention belongs to the technical field of organic synthesis, and relates to an optimization method of a hydrolysis process in a ceftazidime side chain acid active ester synthesis process, which comprises the following steps: adding a ceftazidime side chain acid ethyl ester intermediate into a hydrolysis mother solution prepared from an organic solvent and water, heating, dissolving, adding a catalyst and an impurity inhibitor, continuing heating, and adding alkali liquor for hydrolysis; after the distillation is finished, adding water, stirring, cooling, dissolving by using alkali liquor, adding sodium pyrosulfite, stirring, adding activated carbon, stirring, decoloring, after decoloring, adjusting the acid by using acid liquor, crystallizing, cooling, and carrying out suction filtration to obtain a hydrolysis crude product; adding the hydrolysis crude product into a mixed solvent, pulping and dissolving, controlling the temperature, preserving the heat, refining, cooling, performing suction filtration, and drying to obtain a hydrolysis product finished product. The reaction efficiency and the product purity are remarkably improved, and experimental results show that the product purity of the optimized process can reach 99.5% or above, and the yield can reach 92% or above.

The present invention provides an antimicrobial combination comprising three different antimicrobial agents The first antimicrobial agent is selected from ceftazidime, polymyxin E, polymyxin B, and pharmaceutically acceptable derivatives thereof; the second antimicrobial agent is selected from zidovudine, doxycycline, fosfomycin and pharmaceutically acceptable derivatives thereof; and the third antimicrobial agent is selected from levofloxacin, doxycycline, fosfomycin, meropenem, rifampicin, gentamicin, polymyxin B / E, and pharmaceutically acceptable derivatives thereof; wherein the combination includes at least one of levofloxacin, doxycycline, rifampicin, fosfomycin, or a pharmaceutically acceptable derivative thereof; provided the combination is not (1) polymyxin E / B, zidovudine and rifampicin or (2) ceftazidime, zidovudine and fosfomycin. Also provided is an antimicrobial combination comprising three antimicrobial agents, wherein the first antimicrobial agent is ceftazidime or a pharmaceutically acceptable derivative thereof; the second antimicrobial agent is zidovudine or a pharmaceutically acceptable derivative thereof; and the third antimicrobial agent is polymyxin E or a pharmaceutically acceptable derivative thereof.

The application discloses a drug-resistant gene PA3514 of pseudomonas aeruginosa and application of the drug-resistant gene PA3514. The nucleotide sequence of the PA3514 gene is shown as SEQ ID NO. 1. The application finds that the drug resistance level of a pseudomonas aeruginosa PAS56 strain to ceftazidime is improved by 8 times after knocking out the PA3514 gene. Therefore, the PA3514 gene is related to the ceftazidime drug resistance of the pseudomonas aeruginosa.

The invention relates to a hybridoma cell strain secreting a ceftazidime monoclonal antibody and application of the hybridoma cell strain, and belongs to the technical field of immunodetection. A hybridoma cell strain capable of accurately detecting low-concentration ceftazidime is separated, specifically, a monoclonal antibody secreted by the hybridoma cell strain has good sensitivity and specificity to the ceftazidime, the IC50 value of the monoclonal antibody to the ceftazidime is 0.40 ng / mL, the IC50 value of the monoclonal antibody to the ceftazidime is 0.40 ng / mL, and the IC50 value of the monoclonal antibody to a structural analogue of the ceftazidime is 0.40 ng / mL. According to the present invention, ceftazidime with low concentration can be accurately detected, such as cefazolin, cefradine, cefalexin, cefquinoline and cefalotin, no cross reaction exists, and the specificity is good, such that the low-concentration ceftazidime can be accurately detected.

The invention relates to a preparation method of a ceftazidime impurity G. The preparation method comprises the following step: in an organic solvent, preparing a compound shown as a formula III from a compound shown as a formula I and a compound shown as a formula II under an alkaline condition. And performing deprotection on the compound in the formula III under an acidic condition to prepare the ceftazidime impurity G (a compound in a formula IV). The preparation method provided by the invention has the advantages of low purification difficulty, high yield and high product purity, and provides a basis for quality research of ceftazidime.

This invention discloses a pan-drug-resistant strain of *Pseudomonas aeruginosa* PAS96 and its applications. *Pseudomonas aeruginosa* PAS96 has the accession number GDMCC No: 64767. This bacterium is resistant to levofloxacin, ciprofloxacin, piperacillin, piperacillin / tazobactam, ticarcillin / clavulanic acid, ceftazidime, meropenem, and imipenem. This invention confirmed the resistance of *Pseudomonas aeruginosa* to the aforementioned antibiotics through Kirby-Bauer (K-B) susceptibility testing.

The invention discloses a method for synthesizing tazobactam diphenylmethyl ester as an intermediate product of tazobactam in a micro-channel reactor, which comprises the following steps: (1) respectively pumping a prepared solution 1 and a prepared solution 2 into the micro-channel reactor, and reacting in the micro-channel reactor in sequence; and (2) quenching, extracting, distilling, pulping, growing crystals, carrying out suction filtration and drying the material at the outlet of the microchannel reactor. And the purity is more than 99.5%. The micro-channel reactor is used in the tazobactam preparation process for the first time, the reaction time can be shortened, two phases are efficiently mixed, and the reaction rate is increased. And the whole reactor can realize continuous feeding, is simple in process operation, and has simple synthesis amplification.